{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:43:52Z","timestamp":1782791032755,"version":"3.54.5"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Hypertension is highly prevalent in chronic kidney disease (CKD) and frequently remains uncontrolled despite high treatment rates; resistant hypertension occurs in up to 40% of CKD patients and markedly increases renal and cardiovascular risk. Aldosterone dysregulation plays a central role in this setting, contributing not only to sodium retention and volume expansion but also to inflammation, fibrosis and target-organ damage in the kidney, heart and vasculature. While spironolactone is recommended as the preferable fourth agent in resistant hypertension, its use in advanced CKD is limited by scarce data, and high rates of hyperkalemia and declining kidney function. Aldosterone synthase inhibitors (ASIs) are an emerging therapeutic class that directly suppress aldosterone production. Recent Phase 2 and 3 randomized controlled trials demonstrate that next-generation, selective ASIs produce clinically meaningful reductions in office and ambulatory blood pressure (BP) in patients with uncontrolled and resistant hypertension, with an acceptable safety profile. Early Phase 2 trials have also shown that ASIs are effective in lowering office BP levels in CKD with accompanying substantial reductions in albuminuria. This review examines the potential clinical benefits of aldosterone synthesis targeted therapy in the management of uncontrolled and resistant hypertension in CKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfag013","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:17:33Z","timestamp":1769422653000},"page":"1214-1226","source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6216-9635","authenticated-orcid":false,"given":"Marieta P","family":"Theodorakopoulou","sequence":"first","affiliation":[{"name":"Aristotle University Thessaloniki First Department of Nephrology, Hippokration Hospital, , Thessaloniki ,","place":["Greece"]},{"name":"Clinical Division of Nephrology and Dialysis, Medical University of Vienna Department of Internal Medicine III, , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-227X","authenticated-orcid":false,"given":"Fotini","family":"Iatridi","sequence":"additional","affiliation":[{"name":"Aristotle University Thessaloniki First Department of Nephrology, Hippokration Hospital, , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-2395","authenticated-orcid":false,"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[{"name":"Clinical Division of Nephrology and Dialysis, Medical University of Vienna Department of Internal Medicine III, , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Aristotle University Thessaloniki First Department of Nephrology, Hippokration Hospital, , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026062922484018100_bib1","doi-asserted-by":"publisher","first-page":"ii36","DOI":"10.1093\/ckj\/sfae278","article-title":"Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?","volume":"17","author":"Theodorakopoulou","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026062922484018100_bib2","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026062922484018100_bib3","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.02.001","article-title":"US Renal Data System 2021 annual data report: epidemiology of kidney disease in the United States","volume":"79","author":"Johansen","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026062922484018100_bib4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.amjmed.2007.11.025","article-title":"Hypertension awareness, treatment, and control in chronic kidney disease","volume":"121","author":"Sarafidis","year":"2008","journal-title":"Am J Med"},{"key":"2026062922484018100_bib5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","article-title":"Resistant hypertension: an overview of evaluation and treatment","volume":"52","author":"Sarafidis","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026062922484018100_bib6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.semnephrol.2014.08.001","article-title":"Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population","volume":"34","author":"Sarafidis","year":"2014","journal-title":"Semin Nephrol"},{"key":"2026062922484018100_bib7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2022.04.010","article-title":"Dipping status, ambulatory blood pressure control, cardiovascular disease, and kidney disease progression: a multicenter cohort study of CKD","volume":"81","author":"Borrelli","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026062922484018100_bib8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/MNH.0000000000001089","article-title":"Aldosterone synthase inhibition in chronic kidney disease","volume":"34","author":"Theodorakopoulou","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026062922484018100_bib9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2019.04.032","article-title":"Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease","volume":"96","author":"Alencar de Pinho","year":"2019","journal-title":"Kidney Int"},{"key":"2026062922484018100_bib10","doi-asserted-by":"publisher","first-page":"e034568","DOI":"10.1161\/JAHA.124.034568","article-title":"Trends of blood pressure control in chronic kidney disease among US adults: findings from NHANES 2011 to 2020","volume":"13","author":"Akbari","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026062922484018100_bib11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1053\/j.ajkd.2013.03.025","article-title":"Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain","volume":"62","author":"Gorostidi","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026062922484018100_bib12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026062922484018100_bib13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"2026062922484018100_bib14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.ajkd.2013.11.016","article-title":"Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study","volume":"63","author":"Tanner","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026062922484018100_bib15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","article-title":"Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients","volume":"61","author":"De Nicola","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026062922484018100_bib16","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"2026062922484018100_bib17","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026062922484018100_bib18","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026062922484018100_bib19","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"2026062922484018100_bib20","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1002\/j.2040-4603.2023.tb00256.x","article-title":"Aldosterone: renal action and physiological effects","volume":"13","author":"Johnston","year":"2023","journal-title":"Compr Physiol"},{"key":"2026062922484018100_bib21","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.2174\/1381612825666190306162658","article-title":"Mineralocorticoid receptor antagonists for nephroprotection: current evidence and future perspectives","volume":"24","author":"Sarafidis","year":"2018","journal-title":"Curr Pharm Des"},{"key":"2026062922484018100_bib22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/kidneydial2020019","article-title":"Role of mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"2","author":"Alexandrou","year":"2022","journal-title":"Kidney Dial"},{"key":"2026062922484018100_bib23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026062922484018100_bib24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","article-title":"Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity","volume":"48","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"2026062922484018100_bib25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejphar.2016.05.030","article-title":"Roles of aldosterone in vascular calcification: an update","volume":"786","author":"Gao","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"2026062922484018100_bib26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1210\/me.2010-0193","article-title":"Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display","volume":"25","author":"Yang","year":"2011","journal-title":"Mol Endocrinol"},{"key":"2026062922484018100_bib27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.2005-0004","article-title":"The nongenomic actions of aldosterone","volume":"26","author":"Funder","year":"2005","journal-title":"Endocr Rev"},{"key":"2026062922484018100_bib28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062922484018100_bib29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026062922484018100_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ajh\/hpaf183","article-title":"Risk of hypertension and chronic kidney disease following aldosterone dysregulation","volume":"39","author":"Townsend","year":"2026","journal-title":"Am J Hypertens"},{"key":"2026062922484018100_bib31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922484018100_bib32","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026062922484018100_bib33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MNH.0000000000001067","article-title":"Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors","volume":"34","author":"Helmeczi","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026062922484018100_bib34","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"2026062922484018100_bib35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062922484018100_bib36","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024fbrh9bc4","article-title":"Effect of baxdrostat on albuminuria in treatment-resistant hypertension: SA-PO353","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026062922484018100_bib37","article-title":"HALO Trial. In AHA Congress; The American College of Cardiology: Washington, DC, USA","author":"Bhatt","year":"2023"},{"key":"2026062922484018100_bib38","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062922484018100_bib39","article-title":"Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial","year":"2025"},{"key":"2026062922484018100_bib40","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2026062922484018100_bib41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062922484018100_bib42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"2026062922484018100_bib43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","article-title":"Results from a Phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in participants with varying degrees of renal function","volume":"13","author":"Freeman","year":"2024","journal-title":"Clin Pharm Drug Dev"},{"key":"2026062922484018100_bib44","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, Phase I trial","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026062922484018100_bib45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"2026062922484018100_bib46","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202544j6mmcr","article-title":"Lorundrostat, a novel aldosterone synthase inhibitor (ASI), in participants with uncontrolled hypertension, CKD, and albuminuria: results from explore-CKD","volume":"36","author":"Weir","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026062922484018100_bib47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026062922484018100_bib48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0735-1097(25)00908-8","article-title":"Mechanisms of cardiovascular benefit with finerenone\u2014a causal mediation analysis of the joint effects of systolic blood pressure and albuminuria reduction","volume":"85","author":"Agarwal","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag013\/66590184\/gfag013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/7\/1214\/66590184\/gfag013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/7\/1214\/66590184\/gfag013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:48:50Z","timestamp":1782787730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/7\/1214\/8442228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag013","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,1,27]]}}}